Amneal Pharmaceuticals names Konidaris to CFO

Amneal Pharmaceuticals Inc. announced on Wednesday it has appointed Tasos Konidaris as senior vice president, chief financial officer, effective immediately.

Konidaris will be succeeding Todd Branning, who is no longer serving in the role but will remain available to the Bridgewater-based company through March 31.

Konidaris, who has more than 30 years of corporate finance and leadership experience, most recently served as CFO and board member at Alcresta Therapeutics Inc. Before that, he was the executive vice president, CFO and head of corporate development of Ikaria Inc. He also previously served seven years as senior vice president and CFO of Dun & Bradstreet Corp. as well as held roles at Shering-Plough Corp., Pharmacia Corp., Novartis Corp. and Bristol-Myers Squibb.

“We are pleased to welcome Tasos as Amneal’s Chief Financial Officer. With his unique operations-focused perspective and deep cross-functional leadership experiences in the pharmaceutical industry, he is an excellent fit for Amneal. We are confident Tasos’s insights and expertise will further advance our ongoing efforts to unlock operating efficiencies and strategically deploy capital to reinvigorate the business. We look forward to working closely with him as we build on Amneal’s strong foundation to drive long-term growth and value for our stakeholders in 2020 and beyond,” Amneal co-CEOs Chirag Patel and Chintu Patel said. “We are grateful to Todd for his leadership and contributions to our company, and we thank him for his work in helping Amneal navigate the challenging industry and market conditions we have experienced. We wish him all the best in his future endeavors.”

“With its compelling diversification strategy, extensive portfolio of marketed commercial products and exciting pipeline of generics and specialty therapeutics products, I believe Amneal is building momentum and well-positioned for success. I am excited to work closely with Chirag, Chintu and the rest of the talented leadership team during this important time for the Company,” Konidaris said.